{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:55:05Z","timestamp":1777956905039,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T00:00:00Z","timestamp":1410739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.jns.2014.08.004","type":"journal-article","created":{"date-parts":[[2014,8,10]],"date-time":"2014-08-10T11:46:15Z","timestamp":1407671175000},"page":"116-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["IncobotulinumtoxinA (Xeomin\u00ae) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated"],"prefix":"10.1016","volume":"346","author":[{"given":"Virgilio Gerald H.","family":"Evidente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia L.","family":"Comella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Grafe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0182-6336","authenticated-orcid":false,"given":"Angelika","family":"Hanschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2014.08.004_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","article-title":"EFNS guidelines on diagnosis and treatment of primary dystonias","volume":"18","author":"Albanese","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jns.2014.08.004_bb0010","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.jns.2014.08.004_bb0015","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.08.004_bb0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","article-title":"Content of botulinum neurotoxin in Botox\u00ae\/Vistabel\u00ae, Dysport\u00ae\/Azzalure\u00ae, and Xeomin\u00ae\/Bocouture\u00ae","volume":"10","author":"Frevert","year":"2010","journal-title":"Drugs R D"},{"key":"10.1016\/j.jns.2014.08.004_bb0025","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm \u2014 a randomized trial","volume":"26","author":"Jankovic","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.jns.2014.08.004_bb0030","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00702-013-0998-9","article-title":"Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin\u00ae) injections in blepharospasm","volume":"120","author":"Truong","year":"2013","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2014.08.004_bb0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jns.2014.08.004_bb0040","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00702-013-1048-3","article-title":"A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin\u00ae) in cervical dystonia","volume":"120","author":"Evidente","year":"2013","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2014.08.004_bb0045","series-title":"Tremor Other Hyperkinet Mov (N Y)","article-title":"Efficacy and safety of incobotulinumtoxinA in subjects previously treated with botulinum toxin versus toxin-naive subjects with cervical dystonia","volume":"3","author":"Fernandez","year":"2013"},{"key":"10.1016\/j.jns.2014.08.004_bb0050","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/jnnp-2012-303608","article-title":"Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia","volume":"84","author":"Dressler","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jns.2014.08.004_bb0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm","volume":"113","author":"Roggenk\u00e4mper","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2014.08.004_bb0060","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00702-010-0529-x","article-title":"Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm","volume":"118","author":"Wabbels","year":"2011","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2014.08.004_bb0065","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.08.004_bb0070","series-title":"Botox\u00ae 100U summary of product characteristics","author":"Allergan","year":"2012"},{"key":"10.1016\/j.jns.2014.08.004_bb0075","series-title":"Dysport\u00ae 300U and 500U summary of product characteristics","author":"Ipsen","year":"2012"},{"key":"10.1016\/j.jns.2014.08.004_bb0080","author":"Allergan, Inc."},{"key":"10.1016\/j.jns.2014.08.004_bb0085","author":"Merz Pharmaceuticals GmbH"},{"key":"10.1016\/j.jns.2014.08.004_bb0090","author":"Biopharm"},{"key":"10.1016\/j.jns.2014.08.004_bb0095","series-title":"XEOMIN\u00ae 100U summary of product characteristics","author":"Merz Pharma UK","year":"2012"},{"key":"10.1016\/j.jns.2014.08.004_bb0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","article-title":"Development of resistance to botulinum toxin type A in patients with torticollis","volume":"9","author":"Greene","year":"1994","journal-title":"Mov Disord"},{"key":"10.1016\/j.jns.2014.08.004_bb0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00702-013-1076-z","article-title":"Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox\u00ae) and incobotulinumtoxinA (Xeomin\u00ae)","volume":"121","author":"Dressler","year":"2014","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2014.08.004_bb0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3111\/13696998.2011.653726","article-title":"Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia","volume":"15","author":"Sethi","year":"2012","journal-title":"J Med Econ"},{"issue":"Supplement 1","key":"10.1016\/j.jns.2014.08.004_bb0115","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/j.jns.2013.07.404","article-title":"Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys of patients and physicians","volume":"333","author":"Bensmail","year":"2013","journal-title":"J Neurol Sci"},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2014.08.004_bb0120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0733-8619(08)80005-9","article-title":"Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia","volume":"26","author":"Swope","year":"2008","journal-title":"Neurol Clin"},{"key":"10.1016\/j.jns.2014.08.004_bb0125","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.08.004_bb0130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WNF.0b013e3181b13308","article-title":"Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity","volume":"32","author":"Ka\u0148ovsk\u00fd","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jns.2014.08.004_bb0135","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2340\/16501977-0796","article-title":"Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity","volume":"43","author":"Ka\u0148ovsk\u00fd","year":"2011","journal-title":"J Rehabil Med"},{"key":"10.1016\/j.jns.2014.08.004_bb0140","article-title":"More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system","author":"Mazzocchio","year":"2014","journal-title":"Neuroscientist"},{"key":"10.1016\/j.jns.2014.08.004_bb0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/00207454.2011.623807","article-title":"Somatosensory cortical activation in cervical dystonia and its modulation with botulinum toxin: an fMRI study","volume":"122","author":"Opavsky","year":"2012","journal-title":"Int J Neurosci"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14005176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14005176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:43:17Z","timestamp":1758382997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X14005176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":29,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0022510X14005176"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2014.08.004","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IncobotulinumtoxinA (Xeomin\u00ae) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2014.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}